NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$2.22 -0.09 (-3.90 %)
(As of 12/19/2018 09:00 AM ET)
Previous Close$2.31
Today's Range$2.18 - $2.38
52-Week Range$0.93 - $3.94
Volume468,435 shs
Average Volume257,964 shs
Market Capitalization$219.12 million
P/E Ratio-3.83
Dividend YieldN/A
Beta1.68
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. In addition, the company has developed DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. Further, it develops YUTIQ shorter-actinguveitis for the treatment of posterior segment uveitis; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Additionally, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It sells its products primarily in the United States and Europe. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, and Enigma Therapeutics Limited. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Receive EYPT News and Ratings via Email

Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYPT
Previous Symbol
CUSIPN/A
Phone617-926-5000

Debt

Debt-to-Equity Ratio0.37
Current Ratio2.57
Quick Ratio2.57

Price-To-Earnings

Trailing P/E Ratio-3.83
Forward P/E Ratio-4.72
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.96 million
Price / Sales71.15
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.16 per share
Price / Book13.88

Profitability

EPS (Most Recent Fiscal Year)($0.58)
Net Income$-53,170,000.00
Net Margins-2,622.93%
Return on Equity-193.49%
Return on Assets-66.66%

Miscellaneous

Employees44
Outstanding Shares94,860,000
Market Cap$219.12 million
OptionableOptionable

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions

What is Eyepoint Pharmaceuticals' stock symbol?

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

How were Eyepoint Pharmaceuticals' earnings last quarter?

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) announced its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.06. The firm had revenue of $0.49 million for the quarter, compared to analysts' expectations of $0.70 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 193.49%. View Eyepoint Pharmaceuticals' Earnings History.

When is Eyepoint Pharmaceuticals' next earnings date?

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for Eyepoint Pharmaceuticals.

What price target have analysts set for EYPT?

2 analysts have issued 1-year price objectives for Eyepoint Pharmaceuticals' stock. Their forecasts range from $4.50 to $6.00. On average, they anticipate Eyepoint Pharmaceuticals' stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (11/13/2018)
  • 2. HC Wainwright analysts commented, "We’d like to remind investors that EyePoint Pharmaceuticals has major regulatory and commercial milestones in the near term. Specifically, YUTIQ three-year treatment of posterior uveitis has a PDUFA date of and DEXYCU for post-operative ocular inflammation is slated to be commercially launched in 1H19. If YUTIQ secures FDA approval in the coming month, it would also be launched in 1H19. The company has entered into an agreement with a contract sales organization to ensure a fully trained and seasoned field organization at product launch. In our view, DEXYCU has attractive market prospects as it would be the first FDA-approved drop-less product on the ocular surgery market that allows patients to do away with conventional eye drops used to control inflammation after the surgery." (10/1/2018)

Has Eyepoint Pharmaceuticals been receiving favorable news coverage?

Media headlines about EYPT stock have been trending positive recently, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Eyepoint Pharmaceuticals' key competitors?

Who are Eyepoint Pharmaceuticals' key executives?

Eyepoint Pharmaceuticals' management team includes the folowing people:
  • Ms. Nancy S. Lurker, Pres, CEO & Director (Age 61)
  • Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 68)
  • Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 61)
  • Mr. David J. Price, Chief Financial Officer (Age 55)
  • Mr. Marty Nazzaro, Sr. VP of Operations

Who are Eyepoint Pharmaceuticals' major shareholders?

Eyepoint Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc (1.90%), Vanguard Group Inc. (2.41%), Renaissance Technologies LLC (1.40%), EAM Investors LLC (0.25%), JPMorgan Chase & Co. (0.19%) and Essex Investment Management Co. LLC (0.25%). Company insiders that own Eyepoint Pharmaceuticals stock include Ew Healthcare Partners, LP and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.

Which major investors are selling Eyepoint Pharmaceuticals stock?

EYPT stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and Renaissance Technologies LLC. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

Which major investors are buying Eyepoint Pharmaceuticals stock?

EYPT stock was bought by a variety of institutional investors in the last quarter, including EAM Investors LLC, Regal Investment Advisors LLC, Essex Investment Management Co. LLC, Vanguard Group Inc, Vanguard Group Inc., B. Riley Wealth Management Inc. and Private Advisor Group LLC. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Ew Healthcare Partners, LP and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.

How do I buy shares of Eyepoint Pharmaceuticals?

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyepoint Pharmaceuticals' stock price today?

One share of EYPT stock can currently be purchased for approximately $2.22.

How big of a company is Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals has a market capitalization of $219.12 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 44 workers across the globe.

What is Eyepoint Pharmaceuticals' official website?

The official website for Eyepoint Pharmaceuticals is http://www.eyepointpharma.com.

How can I contact Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]


MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel